UNCY icon

Unicycive Therapeutics

4.43 USD
-0.22
4.73%
At close Jul 18, 4:00 PM EDT
After hours
4.57
+0.14
3.16%
1 day
-4.73%
5 days
-11.40%
1 month
-33.68%
3 months
-27.38%
6 months
-32.26%
Year to date
-44.07%
1 year
8.85%
5 years
-92.43%
10 years
-92.43%
 

About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Employees: 22

0
Funds holding %
of 7,321 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

1.71% less ownership

Funds ownership: 59.44% [Q4 2024] → 57.73% (-1.71%) [Q1 2025]

6% less funds holding

Funds holding: 31 [Q4 2024] → 29 (-2) [Q1 2025]

30% less capital invested

Capital invested by funds: $49M [Q4 2024] → $34.5M (-$14.6M) [Q1 2025]

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$60
1,254%
upside
Avg. target
$75
1,593%
upside
High target
$90
1,932%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
1,932%upside
$90
Buy
Assumed
27 May 2025
Guggenheim
Vamil Divan
1,254%upside
$60
Buy
Initiated
21 Apr 2025

Financial journalist opinion

Based on 10 articles about UNCY published over the past 30 days

Neutral
Business Wire
11 hours ago
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $UNCY--UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
Neutral
PRNewsWire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Neutral
GlobeNewsWire
5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Neutral
PRNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Neutral
GlobeNewsWire
1 week ago
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
LOS ALTOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications.
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Neutral
PRNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Neutral
GlobeNewsWire
1 week ago
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET.
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Neutral
PRNewsWire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Neutral
GlobeNewsWire
2 weeks ago
INVESTOR ALERT: Investigation of Unicycive Therapeutics, Inc. (UNCY) Announced by Holzer & Holzer, LLC
ATLANTA, June 30, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) complied with federal securities laws. On June 30, 2025, Unicycive “announced that the U.S. Food and Drug Administration (FDA) has issued a CRL for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.” Following this news, the price of the Company's stock dropped.
INVESTOR ALERT: Investigation of Unicycive Therapeutics, Inc. (UNCY) Announced by Holzer & Holzer, LLC
Neutral
GlobeNewsWire
2 weeks ago
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
--Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC)
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Charts implemented using Lightweight Charts™